Publication | Open Access

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma

Therapy ConfersTumor ImmunologyImmune-evasive Tumor MicroenvironmentCancer ImmunosurveillanceMedicineMelanomaImmunologyImmune Checkpoint InhibitorImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentSkin Cancer